Received 8 August 2011
aAnkara University, Department of Chemistry, 06100 Tandogan, Ankara, Turkey,bAnadolu University, Faculty of Science, Department of Chemistry, 26470 Yenibaglar, Eskisehir, Turkey, and cHacettepe University, Department of Physics, 06800 Beytepe, Ankara, Turkey
Correspondence e-mail: firstname.lastname@example.org
The title benzimidazole molecule, C8H8N4O2·2H2O, is planar with a maximum deviation of 0.079 (2) Å (for one of the O atoms in the nitro group). It crystallized as a dihydrate and intermolecular O-HO and N-HO hydrogen bonds link the uncoordinated water molecules, and the nitro and amine groups, respectively. In the crystal, N-HO, O-HN, O-HO and C-HO hydrogen bonds link the molecules to form a three-dimensional network. A - contact between the benzene rings, [centroid-centroid distance = 3.588 (1) Å] may further stabilize the crystal structure.
For the antitumor, antihelmintic, antibacterial, virucidal and fungucidal properties of benzimidazole derivatives, see: Refaat (2010); Laryea et al. (2010); Horton et al. (2003); Spasov et al. (1999); Soula & Luu-Duc (1986). For the coordination and corrosion inhibitor abilities of benzimidazoles, see: Kuznetsov & Kazansky (2008); Subramanyam & Mayanna (1985). For the use of benzimidazole derivatives as photographic materials and dyes, see: Hoffmann et al. (2011); Alamgir et al. (2007). For related structures, see: Hökelek et al. (2002); Dinçer et al. (2011).
Data collection: APEX2 (Bruker, 2007); cell refinement: SAINT (Bruker, 2007); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 1997); software used to prepare material for publication: WinGX (Farrugia, 1999).
Supplementary data and figures for this paper are available from the IUCr electronic archives (Reference: SU2305 ).
The authors are indebted to Anadolu University and the Medicinal Plants and Medicine Research Centre of Anadolu University, Eskisehir, Turkey, for use of the X-ray diffractometer.
Alamgir, M., Black, D. S. C. & Kumar, N. (2007). Top. Heterocycl. Chem. 9, 87-118.
Bruker (2001). SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
Bruker (2007). APEX2 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
Dinçer, S., Gönülalan, G., Tercan, B. & Hökelek, T. (2011). Acta Cryst. E67, o806-o807.
Farrugia, L. J. (1997). J. Appl. Cryst. 30, 565.
Farrugia, L. J. (1999). J. Appl. Cryst. 32, 837-838.
Hoffmann, H. S., Stefani, V., Benvenutti, E. V., Costa, T. M. H. & Gallas, M. R. (2011). Mater. Chem. Phys. 126, 97-101.
Hökelek, T., Dinçer, S. & Kiliç, E. (2002). Cryst. Res. Technol. 37, 1138-1142.
Horton, D. A., Bourne, G. T. & Smythe, M. L. (2003). Chem. Rev. 103, 893-930.
Kuznetsov, Y. I. & Kazansky, L. P. (2008). Russ. Chem. Rev. 77, 219-232.
Laryea, D., Gullbo, J., Isakssoon, A., Larsson, R. & Nygren, P. (2010). Anti-Cancer Drugs, 21, 33-42.
Refaat, H. M. (2010). Eur. J. Med. Chem. 45, 2949-2956.
Sheldrick, G. M. (2008). Acta Cryst. A64, 112-122.
Soula, C. & Luu-Duc, C. (1986). Lyon Pharm. 37, 297-302.
Spasov, A. A., Yozhitsa, I. N., Bugaeva, L. I. & Anisimova, V. A. (1999). Pharm. Chem. J. 33, 232-243.
Subramanyam, N. C. & Mayanna, S. M. (1985). Corros. Sci. 25, 163-169.